Engineered immune cell as well as preparation and application thereof

By expressing chimeric antigen receptors targeting TROP2 in CAR-T cells, the problems of target heterogeneity and immune escape in the prior art were solved, and the killing ability of TROP2-positive tumor cells was significantly improved, and the tumor was reduced Recurrence risk achieves efficient treatment of various solid tumors.

CN119306846APending Publication Date: 2025-01-14GUANGZHOU BIOSYNGEN CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202410937898.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-07-14
Filing Date
2024-07-12
Publication Date
2025-01-14

AI Technical Summary

Technical Problem

The existing CAR-T cell therapy is prone to poor treatment effect due to target heterogeneity and immune escape when treating malignant tumors, especially the lack of recognition and clearance of TROP2-positive tumor cells, resulting in tumor recurrence.

Method used

Develop a chimeric antigen receptor (CAR) protein targeting engineered immune cells expressed by TROP2, including CAR-T cells, by expressing single-chain antibodies (scFv) that specifically bind TROP2, and transmembrane domains, to bind to co- Stimulates the signaling domain and enhances the recognition and killing ability of tumor cells.

Benefits of technology

It improves the killing efficacy of TROP2-positive tumor cells, reduces the risk of tumor recurrence, and significantly enhances the therapeutic effect on a variety of solid tumors, including colorectal cancer, pancreatic cancer, esophageal cancer, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004941903490000191
    Figure BDA0004941903490000191
  • Figure HDA0004941903500000011
    Figure HDA0004941903500000011
  • Figure HDA0004941903500000021
    Figure HDA0004941903500000021
Patent Text Reader

Abstract

The invention provides an engineered immune cell as well as preparation and application thereof. According to the invention, the TROP2-targeted chimeric antigen receptor is expressed in the immune cell, so that the killing effect of the engineered immune cell on tumor cells is unexpected.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof

    US5350674A

  • Gene therapy

    US5399346A

  • Delivery of exogenous DNA sequences in a mammal

    US5580859A

  • Adenovirus vectors for gene therapy

    US5585362A

  • Induction of a protective immune response in a mammal by injecting a DNA sequence

    US5589466A